These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31590041)

  • 1. Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.
    Ansari AJ; Joshi G; Yadav UP; Maurya AK; Agnihotri VK; Kalra S; Kumar R; Singh S; Sawant DM
    Bioorg Chem; 2019 Dec; 93():103314. PubMed ID: 31590041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
    Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
    Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
    Zhang B; Liu Z; Xia S; Liu Q; Gou S
    Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
    El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
    Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
    El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
    Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
    Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elaboration of tetra-orthogonally-substituted aromatic scaffolds towards novel EGFR-kinase inhibitors.
    Close AJ; Jones RN; Ocasio CA; Kemmitt P; Roe SM; Spencer J
    Org Biomol Chem; 2016 Sep; 14(35):8246-52. PubMed ID: 27453149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
    Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
    ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
    Li ED; Lin Q; Meng YQ; Zhang LY; Song PP; Li N; Xin JC; Yang P; Bao CN; Zhang DQ; Zhang Y; Wang JK; Zhang QR; Liu HM
    Eur J Med Chem; 2019 Jun; 172():36-47. PubMed ID: 30939352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 4-arylaminoquinazolines bearing
    Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.